Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|September 5, 2003
Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cellsDavid Y Bouffard, Jacques Jolivet, Lorraine Leblond, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical developmentHenriette Gourdeau, Lorraine Leblond, Bettina Hamelin, et al.Cancer Investigation|April 9, 2004
Action of troxacitabine on cells transduced with human cytidine deaminase cDNAAnne-Julie Boivin, Henriette Gourdeau, Richard L MomparlerAnti-Cancer Drugs|March 12, 2010
TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activationNadia Boufaied, My-Anh Wioland, Pierre Falardeau, et al.Molecular Cancer Therapeutics|December 14, 2002
BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activityLorraine Leblond, Giorgio Attardo, Bettina Hamelin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2007
Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modificationsJia-Chi Wang, Louis R Bégin, Nathalie G Bérubé, et al.Journal of Molecular Signaling|November 4, 2010
TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signalingPaul M Campbell, Nadia Boufaied, James J Fiordalisi, et al.Cancer Chemotherapy and Pharmacology|July 12, 2007
Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligandHenriette Gourdeau, James B McAlpine, Maxime Ranger, et al.British Journal of Haematology|March 11, 2004
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluationNada Orsolic, Francis J Giles, Henriette Gourdeau, et al.Pageof 4